History

Developed by Eli Lilly as a once-weekly triple agonist building on its tirzepatide work. First-in-human Phase 1b results in type 2 diabetes were published in The Lancet in 2022, and a Phase 2 obesity trial in the New England Journal of Medicine in 2023 reported up to about 17.5% mean weight reduction at 24 weeks, drawing wide attention. Pivotal Phase 3 studies (the TRIUMPH program) began reading out in 2025-2026; it remains investigational and unapproved.

Retatrutide (Lilly code LY3437943) is an investigational injectable drug for obesity and type 2 diabetes. It has produced some of the largest weight-loss figures seen in trials so far, but as of June 2026 it is not approved anywhere and its pivotal Phase 3 data have not yet been peer-reviewed.

What it is

Retatrutide is a once-weekly subcutaneous peptide that activates three gut and metabolic hormone receptors at once: GLP-1, GIP, and glucagon. Approved drugs target one (semaglutide) or two (tirzepatide) of these. Adding glucagon-receptor activity is thought to raise energy expenditure on top of appetite suppression. It is developed by Eli Lilly and remains an experimental compound.

The claims

Online sellers and forums promote retatrutide as the most powerful weight-loss drug yet, with claims of 25 percent or more body-weight reduction, liver-fat clearance, and diabetes “reversal.” Some marketing frames it as a successor to tirzepatide that you can obtain now. Both the efficacy framing and the availability framing need scrutiny.

What the evidence actually shows

The human data are real and, for weight loss, strong in quality. In a published 48-week Phase 2 randomized trial in 338 adults with obesity (Jastreboff et al., NEJM, 2023), the 12 mg dose produced about 24 percent mean weight loss (−24.2%) versus roughly 2 percent (−2.1%) on placebo. A separate Phase 2 trial in 281 people with type 2 diabetes (Rosenstock et al., The Lancet, 2023) showed meaningful HbA1c and weight reductions, and a 98-person Phase 2a substudy reported dose-dependent liver-fat reductions of roughly 82 percent at 24 weeks (and about 86 percent by 48 weeks) at the 12 mg dose in people with fatty liver disease.

In May 2026 Lilly announced topline Phase 3 results (TRIUMPH-1, roughly 2,300 participants, 80 weeks): about 28 percent average weight loss on 12 mg versus about 2 percent on placebo, with a longer blinded extension reaching about 30 percent at 104 weeks in a subset. An earlier Phase 3 readout in obesity plus knee osteoarthritis (TRIUMPH-4, December 2025) reported similar weight loss (about 29 percent, an average of 71.2 lb at the top dose) alongside reduced knee pain.

The important caveats: the Phase 3 results exist only as company press releases, not peer-reviewed publications. Several TRIUMPH trials had not fully reported as of mid-2026, and there are no long-term safety or cardiovascular-outcome data. This is a promising but unfinished evidence base.

Legal and regulatory status

Retatrutide is not approved by the FDA, EMA, or any major regulator as of June 2026. It is investigational and cannot be legally prescribed or sold for human use outside a clinical trial. Lilly has indicated it expects to file a U.S. application around late 2026, which would put any possible approval no earlier than 2027. Products sold online as “retatrutide” are unapproved and unregulated, with no guarantee of identity, purity, or dose.

For athletes: retatrutide is not specifically named on WADA’s 2026 Prohibited List, and the GLP-1 class is not banned — semaglutide and tirzepatide are on WADA’s 2026 Monitoring Program (watched for possible misuse), not prohibited. That said, retatrutide is an unapproved investigational substance, and WADA’s rules separately prohibit substances that are not approved for human therapeutic use (category S0). Any competing athlete should treat its status as unsettled and confirm with their anti-doping authority before use.

Safety

In trials the most common side effects were gastrointestinal — nausea, vomiting, diarrhea, constipation — mostly mild to moderate and concentrated during dose escalation. A modest increase in heart rate was observed at higher doses. Measured liver fat improved rather than worsened, with no hepatotoxicity signal reported through 48 weeks in the studies above. However, long-term safety is unknown, and none of this applies to unregulated gray-market product, which carries additional and unquantified risks.

Bottom line

Retatrutide has genuinely impressive trial results and may become an important obesity drug, but it is still experimental, not yet peer-reviewed at the Phase 3 level, and not legally available. Anything sold today is unapproved. Nothing here is medical advice.

Evidence grade: Preliminary human.